Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Sarepta Therapeutics's operating assets for the quarter that ended in Mar. 2026 was $2,526 Mil. Sarepta Therapeutics's operating liabilities for the quarter that ended in Mar. 2026 was $637 Mil. Sarepta Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was $3,350 Mil. Therefore, Sarepta Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.56.
Sarepta Therapeutics Scaled Net Operating Assets Related Terms
Sarepta Therapeutics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics Scaled Net Operating Assets Chart
LTS:0L35 vs ZYME, BCAX, INVA: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Sarepta Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.56 mean?
Sarepta Therapeutics (LTS:0L35) has a Scaled Net Operating Assets of 0.56 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Scaled Net Operating Assets too high?
Sarepta Therapeutics' current Scaled Net Operating Assets is 0.56. Overall, Sarepta Therapeutics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Scaled Net Operating Assets compare to ZYME and BCAX?
Sarepta Therapeutics' Scaled Net Operating Assets of 0.56 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Scaled Net Operating Assets is 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (LTS:0L35) is currently considered Possible Value Trap. The stock's GF Value™ is $131.71, compared to a current price of $19.09 — trading 85.5% below its estimated fair value. The current Scaled Net Operating Assets is 0.56. Sarepta Therapeutics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Sarepta Therapeutics (LTS:0L35), the current Scaled Net Operating Assets is 0.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of $19.09 is trading 85.5% below its estimated GF Value™ of $131.71.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0L35:
Scaled Net Operating Assets: 0.56
GF Value™: $131.71 vs. price of $19.09 (85.5% below fair value)
No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
51GF Score
Get the complete analysis for LTS:0L35
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0L35 has been successfully added to your 
